JSPR vs. DCGO, AVXL, CRBU, MGTX, SOPH, TNYA, CADL, BDTX, IVVD, and ADAP
Should you be buying Jasper Therapeutics stock or one of its competitors? The main competitors of Jasper Therapeutics include DocGo (DCGO), Anavex Life Sciences (AVXL), Caribou Biosciences (CRBU), MeiraGTx (MGTX), SOPHiA GENETICS (SOPH), Tenaya Therapeutics (TNYA), Candel Therapeutics (CADL), Black Diamond Therapeutics (BDTX), Invivyd (IVVD), and Adaptimmune Therapeutics (ADAP). These companies are all part of the "medical" sector.
Jasper Therapeutics (NASDAQ:JSPR) and DocGo (NASDAQ:DCGO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, community ranking, valuation, earnings, risk and dividends.
Jasper Therapeutics has a beta of 2.25, meaning that its stock price is 125% more volatile than the S&P 500. Comparatively, DocGo has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500.
Jasper Therapeutics currently has a consensus price target of $64.29, indicating a potential upside of 179.26%. DocGo has a consensus price target of $7.75, indicating a potential upside of 151.62%. Given Jasper Therapeutics' higher probable upside, analysts plainly believe Jasper Therapeutics is more favorable than DocGo.
DocGo has higher revenue and earnings than Jasper Therapeutics. Jasper Therapeutics is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.
79.9% of Jasper Therapeutics shares are held by institutional investors. Comparatively, 56.4% of DocGo shares are held by institutional investors. 2.7% of Jasper Therapeutics shares are held by insiders. Comparatively, 13.8% of DocGo shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
DocGo received 15 more outperform votes than Jasper Therapeutics when rated by MarketBeat users. However, 83.87% of users gave Jasper Therapeutics an outperform vote while only 73.21% of users gave DocGo an outperform vote.
DocGo has a net margin of 2.98% compared to Jasper Therapeutics' net margin of 0.00%. DocGo's return on equity of 6.20% beat Jasper Therapeutics' return on equity.
In the previous week, Jasper Therapeutics had 6 more articles in the media than DocGo. MarketBeat recorded 24 mentions for Jasper Therapeutics and 18 mentions for DocGo. Jasper Therapeutics' average media sentiment score of 0.92 beat DocGo's score of 0.59 indicating that Jasper Therapeutics is being referred to more favorably in the media.
Summary
DocGo beats Jasper Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Jasper Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding JSPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Jasper Therapeutics Competitors List
Related Companies and Tools
